Dr. Hollingshead was the president and chief executive officer of Insulet Corporation from 2022 to 2025 and served as a director there from 2019 to 2025. From 2020 to 2022, he served as president of the sleep and respiratory care business at ResMed Inc. Prior to that, he served as president of the sleep business from 2017 to 2020, and from 2011 to 2017, he held numerous positions at ResMed, including president, Americas, chief strategy officer, and president, Ventures & Initiatives. Before that, Dr. Hollingshead spent nearly two decades in strategy consulting, including as a senior partner in the strategy and life sciences practices at Deloitte Consulting and as managing partner at Monitor Group, a U.S. strategy consulting firm, including serving in various global roles, including founder and managing partner and european marketing strategy practice in the U.K. and office managing partner in Istanbul.
Dr. Hollingshead holds a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University, and a master’s degree and Ph.D. in political science from the University of California, Berkely, where he was awarded a graduate student fellowship by the National Science Foundation.
Asia Pacific
North America
